Literature DB >> 15565647

Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.

Susan Kasper1.   

Abstract

Genetically engineered mouse models have been generated to study the molecular basis of prostate cancer (PCa) development, progression, and metastasis. Selection of a prostate-specific promoter, such as the probasin (PB) and prostate specific antigen (PSA) promoters, is critical for generating sufficient levels of transgene expression to elicit a phenotypic response. To date, target genes have included growth factors, cell cycle regulators, pro- and anti-apoptotic proteins, steroid hormone and growth factor receptors, oncogenes, tumor suppressors, and homeobox genes. The experimental approaches used to generate these mouse models include overexpression of the transgene, knock-out/knock-in of transgene expression and conditional regulation of expression using Cre/lox technology. This review summarizes the promoters, which have been utilized to create genetically engineered mouse models for PCa. Furthermore, the effects of gene disruption on promoting low- and high-grade intraepithelial neoplasia (LGPIN and HGPIN, respectively), locally invasive carcinoma and metastatic lesions will be discussed. To date, the PB-Cre4 x PTENloxp/loxp model appears to be the only model that represents the entire continuum of prostate adenocarcinoma development, tumor progression, and metastasis, although models that develop prostatic neuroendocrine (NE) cancer can be generated by disrupting one genetic event. Indeed, analysis of bigenic mouse models indicates that two genetic events are generally required for progression from HGPIN to locally invasive adenocarcinoma and that two to five genetic events can promote metastasis to distant sites. Studying the effects of genetic perturbation on PCa biology will increase our understanding of the disease process and potentially provide targets for developing novel therapeutic approaches. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15565647     DOI: 10.1002/jcb.20339

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  31 in total

Review 1.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

2.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

3.  Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.

Authors:  Uddhav P Kelavkar; Anil V Parwani; Scott B Shappell; W David Martin
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

4.  A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate.

Authors:  Varsha Rao; Jamie C Heard; Helya Ghaffari; Aminah Wali; Laura N Mutton; Charles J Bieberich
Journal:  Prostate       Date:  2012-02-01       Impact factor: 4.104

5.  Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.

Authors:  Simon A Williams; Yi Xu; Angelo M De Marzo; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

6.  Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.

Authors:  Yin Liu; Jun Qin Mo; Qiande Hu; Gregory Boivin; Linda Levin; Shan Lu; Dianer Yang; Zhongyun Dong; Shan Lu
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.

Authors:  Girish V Shah; Anbalagan Muralidharan; Shibu Thomas; Mitan Gokulgandhi; Mudit Mudit; Mohammad Khanfar; Khalid El Sayed
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

8.  Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Authors:  Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

9.  Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.

Authors:  Yuqi Cai; David Balli; Vladimir Ustiyan; Logan Fulford; Andrea Hiller; Vinko Misetic; Yufang Zhang; Andrew M Paluch; Susan E Waltz; Susan Kasper; Tanya V Kalin
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

10.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.